EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Imlunestrant (Primary)
- Indications Carcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Pharmacodynamics
- Acronyms EMBER-2; EMBER-2 WOO
- Sponsors Eli Lilly and Company
- 24 Oct 2023 Results (n=75) reporting final pharmacodynamic (PD) biomarker data from the preoperative EMBER-2 WOO study, including the expanded data at the 200 mg dose level presented at the 48th European Society for Medical Oncology Congress
- 06 Oct 2023 According to an Eli Lilly and Company media release, the company will be presented the data from this study at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid.
- 29 Mar 2023 Status changed from active, no longer recruiting to completed.